Science Explorer Back to mapMap
Discussion
Company · Uppsala · Sweden

Biovica (Sweden)

biovica.comROR OpenAlex
Research works
15
▼ 41% vs 2018-21
Citations
126
8.6 per fractional work
Top-10% rate
4.7%
all institutions 10.0%
Open access
35%
world 40%
International
62%
world 18%
Biovica (Sweden)

Not ranked overall: Biovica (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Biovica (Sweden) work in?

In all years, 83% of research at Biovica (Sweden) is in Health Sciences, 16% in Life Sciences. Its largest fields are Medicine (82%), Biochemistry, Genetics and Molecular Biology (12%), Immunology and Microbiology (4%). It does 2.4× the world's share of Health Sciences.

Health Sciences: 12 fractional works · 83.0% of its workMedicine: 12 fractional works · 81.7% of its workOncology: 5 fractional works · 32.0% of its workPulmonary and Respiratory Medicine: 4 fractional works · 30.5% of its workGenetics: 1 fractional works · 6.2% of its workEpidemiology: 1 fractional works · 5.5% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 3.1% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.9% of its workInfectious Diseases: 0 fractional works · 1.6% of its workHematology: 0 fractional works · 0.5% of its workGastroenterology: 0 fractional works · 0.5% of its workNursing: 0 fractional works · 0.7% of its workNutrition and Dietetics: 0 fractional works · 0.7% of its workVeterinary: 0 fractional works · 0.5% of its workSmall Animals: 0 fractional works · 0.5% of its workLife Sciences: 2 fractional works · 16.1% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 11.7% of its workCancer Research: 1 fractional works · 6.2% of its workGenetics: 0 fractional works · 2.9% of its workMolecular Biology: 0 fractional works · 2.7% of its workImmunology and Microbiology: 1 fractional works · 4.4% of its workImmunology: 1 fractional works · 3.6% of its workVirology: 0 fractional works · 0.7% of its workSocial Sciences: 0 fractional works · 0.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.7% of its workEconomics and Econometrics: 0 fractional works · 0.7% of its workPhysical Sciences: 0 fractional works · 0.2% of its workChemistry: 0 fractional works · 0.2% of its workOrganic Chemistry: 0 fractional works · 0.2% of its workALL ITS WORKBiovica (Sweden)15fractional works, all years
Life Sciences16%Physical Sciences0%Health Sciences83%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 7 fields, with their numbers
    1. Medicine1281.7%
    2. Nursing00.7%
    3. Veterinary00.5%
    1. Biochemistry, Genetics and Molecular Biology211.7%
    2. Immunology and Microbiology14.4%
    1. Economics, Econometrics and Finance00.7%
    1. Chemistry00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Biovica (Sweden)?

Ranked on the quality score, Mattias Bergqvist lead among researchers whose main affiliation is Biovica (Sweden).

  1. 1 Mattias Bergqvist Sweden · #2,313,692 worldwide 629 citations · 145 works
All ranked researchers at Biovica (Sweden)

What are the most cited papers from Biovica (Sweden)?

The most cited paper from Biovica (Sweden) is "Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib" (Nusayba Ali Bagegni, Shana N. Thomas, Ning Liu et al., 2017), with 74 citations. Next come "Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy" (55) and "A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer" (44).

Most cited papers
#PaperReleasedCitations
1 Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib Nusayba Ali Bagegni, Shana N. Thomas, Ning Liu et al. · Breast Cancer Research Open access 21 Nov 2017 74
2 Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy Martina Bonechi, Francesca Galardi, Chiara Biagioni et al. · Oncotarget Open access 26 Mar 2018 55
3 A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer Jan Trøst Jørgensen, Henrik Winther, Jon Askaa et al. · Frontiers in Oncology Open access 23 Jul 2021 44
4 Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) Amelia McCartney, Chiara Biagioni, Gaia Schiavon et al. · European Journal of Cancer 3 May 2019 42
5 Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial Judith Bjöhle, Jenny Bergqvist, J. Simon Gronowitz et al. · Breast Cancer Research and Treatment Jun 2013 40
All 34 most cited papers, with filters and sorting

Which research topics does Biovica (Sweden) publish most on?

By volume in 2022-now: Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers and Lung Cancer Treatments and Mutations.

Advanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksHER2/EGFR in Cancer Rese…1HER2/EGFR in Cancer Research: 1 fractional worksCancer Immunotherapy and…0Cancer Immunotherapy and Biomarkers: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksPARP inhibition in cancer therapy: 0 fractional worksNeuroendocrine Tumor Res…0Neuroendocrine Tumor Research Advances: 0 fractional worksCancer-related Molecular Pathways: 0 fractional worksChronic Lymphocytic Leukemia Research: 0 fractional worksGrowth Hormone and Insulin-like Growth Factors: 0 fractional worksBreast Cancer Treatment Studies: 0 fractional works
Pulmonary and Respiratory MedicineOncologyEpidemiologyGenetics2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  2. 2 HER2/EGFR in Cancer Research Oncology 1 works
  3. 3 Cancer Immunotherapy and Biomarkers Oncology 0 works
  4. 4 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  5. 5 PARP inhibition in cancer therapy Oncology 0 works
  6. 6 Neuroendocrine Tumor Research Advances Epidemiology 0 works
  7. 7 Cancer-related Molecular Pathways Oncology 0 works
  8. 8 Chronic Lymphocytic Leukemia Research Genetics 0 works
  9. 9 Growth Hormone and Insulin-like Growth Factors Endocrinology, Diabetes and Metabolism 0 works
  10. 10 Breast Cancer Treatment Studies Cancer Research 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available34.6%not open65.4%

World: 40% of research is openly available.

with international co-authors61.7%domestic only38.3%

World: 18% is written across borders.

How has Biovica (Sweden)'s research output changed?

Output in 2022-2025 was 41% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Biovica (Sweden) as a percentage of every work published that year, 0.0000034% in 2024.

still counting0.000025%0.000050%0.000075%Biovica (Sweden)0.000016% in 20251990200020102020

Fractional works of Biovica (Sweden) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Uppsala

All research institutions in Uppsala

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Biovica (Sweden). Posts are plain text and can be reported.